About e-Therapeutics
e-Therapeutics is a systems biology drug discovery company. We possess efficient proprietary methods for discovering new bioactive compounds, de-risking candidates against efficacy and safety, discovering combinations of compounds with specific therapeutic effects, and discovering surprising new indications for existing compounds.
We are a UK based company with collaborative links to other companies and organisations across the UK and in India, China and the United States.
Systematic Drug Discovery
In all of life that is relevant to disease, there are millions of proteins. Every drug compound binds in varying degrees to many different proteins. The huge variety of possible protein targets, and the large variety of patterns of possible binding with proteins create an enormous range of possible interactions between a drug molecule and any biological system. For this fundamental reason, the biological effects of a molecule's interactions with pathogenic, pathological and normal cells have been very difficult to predict.
e-Therapeutics has developed proprietary systems biology tools that can predict the biological effect of interference with one or many proteins in a cell. These very fast processes have been shown to predict biological effects accurately.
e-Therapeutics uses these capabilities to search for new drugs across several therapeutic areas; to search for new clinical uses for existing drugs; and to identify the probability of drug-drug interactions and toxicity.
Drug Discovery Programme
e-Therapeutics proprietary discovery program is currently focused on novel antimicrobial compounds and anti-cancer agents, and especially on the discovery of compounds with novel modes of action, and so reduced problems of bacterial resistance.
New Clinical Uses Programme
e-Therapeutics searches for novel clinical uses for existing drugs, and for novel indications for combinations of drugs. These processes can search the entire formulary in less time than is required for a single clinical trial. We use these processes to focus development of novel therapies using existing drugs, novel therapies using combinations of existing drugs, and on the extension of protection for existing therapies nearing patent expiry.
Drug Interaction Programme
It is well known that patients taking several drugs can suffer from interactions between them. Pharmaceutical development and regulation, however, lacks useful tools for testing and de-risking against these sometimes disastrous interactions. e-Therapeutics tools search for the biological effects of combinations of drugs, to determine the probability of interactions in target patient populations taking multiple drugs. The company’s current portfolio is in anti-infectives, cancer, central nervous system and asthma.